Protecting the public health by strengthening the Food and Drug Administration's authority over tobacco products
Article Abstract:
A lawyer representing the National Center for Tobacco-Free Kids believes Congress should give the FDA full authority to regulate tobacco products. In 2000, the US Supreme Court ruled 5-to-4 that Congress had never given the agency such power. Nevertheless, the FDA is the only agency has the personnel and the scientific expertise to regulate tobacco products.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Beyond the tobacco settlement
Article Abstract:
Congress should give the FDA broad powers to regulate tobacco products. The Master Settlement Agreement of 1998 has had a minimal effect on the industry, which has simply shifted its advertising dollars to venues that were not covered by the agreement. In addition, most states have not spend their settlement on tobacco prevention programs.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
The tobacco settlement
Article Abstract:
The 1997 tobacco settlement may not have the desired effect. It fines the tobacco industry $368.5 billion to recover the costs of treating smoke-related illnesses but the industry would be immune from future prosecution. In addition, the settlement proposes raising the price of cigarettes by 62 cents a pack so the industry can pay the fine. However, research indicates that a price increase of $1.50 to $2.00 per pack is needed to deter many young people from smoking. The industry should also have to pay severe penalties for marketing cigarettes to teenagers.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action. Prescription drug use in pregnancy
- Abstracts: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Clearing the smoke on nicotine and angiogenesis
- Abstracts: Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1
- Abstracts: Lack of relationship between diurnal rhythms in fetal heart rate and maternal cortisol concentration. Twenty-four-hour pattern of cortisol in the human fetus at term
- Abstracts: Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection